5243722026-01-012026-03-315243722026-03-315243722025-03-315243722025-04-012026-03-315243722026-01-012026-03-31in-capmkt:OtherExpenses1Member5243722025-04-012026-03-31in-capmkt:OtherExpenses1Member5243722026-03-31OtherNoncurrentFinancialAssetsDomain15243722026-03-31OtherNoncurrentFinancialAssetsDomain25243722026-03-31OtherNoncurrentFinancialAssetsDomain35243722026-03-31OtherNoncurrentAssetsDomain15243722026-03-31OtherCurrentFinancialAssetsDomain15243722026-03-31OtherCurrentAssetsDomain15243722026-03-31OtherNoncurrentFinancialLiabilitiesDomain15243722026-03-31OtherCurrentFinancialLiabilitiesDomain15243722026-03-31OtherCurrentLiabilitiesDomain15243722026-01-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15243722025-04-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15243722026-01-012026-03-31AuditorDomain15243722026-01-012026-03-31in-capmkt:AuditedMember5243722026-03-31in-capmkt:AuditedMember5243722026-01-012026-03-31in-capmkt:AdjustedMember5243722026-03-31in-capmkt:AdjustedMember5243722026-01-012026-03-31AuditQualification1iso4217:INRiso4217:INRxbrli:shares524372ORCHPHARMANOTLISTEDINE191A01027ORCHID PHARMA LIMITEDMain BoardEquity2025-04-012026-03-312026-05-252026-05-19INRLakhsQuarterlyFourth quarterSingle segmentPharmaceuticals2026-05-2515:00:002026-05-2519:15:00trueCash Flow IndirectStatement on impact of audit qualification2026-01-012026-03-31AuditedConsolidated23760730007341900024494920001209460000475900029934900020878200030912000886780003850760002227016000222476000539200022786800001700017000022785100000099510002378020008820000246622000507191000104.694.69004.694.691. The above results for the quarter and year ended March 31 , 2026 as reviewed and recommended by the Audit committee of the Board, has been approved by the Board of Directors at its meeting held on May 25, 2026.The statutory auditors of the company have expressed an unmodified opinion on the audited Standalone results and a modified opinion on the audit of the Consolidated results <BR> 2 The Statement has been prepared in accordance with the recognition and measurement principles of the Companies Indian Accounting Standards ("Ind AS") as prescribed under Section 133 of the Companies Act, 2013, read with the Companies (Indian Accounting Standards) Rules, 2015, as amended from time to time and other recognized accounting practices and policies generally accepted in India, to the extent applicable. <BR> 3 a) The Government of India had consolidated 29 existing labour legislations into a unified framework comprising four Labour Codes collectively referred to as the 'New Labour Codes', which became effective from 21st November 2025. However, the new Rules are yet be notified even as on date. <BR> During the quarter ended December 2025, based on its preliminary understanding of the new Labour Codes, the Company recognised a provision of Rs. 711 .27 lakhs towards incremental estimated liabilities for past service cost relating to gratuity and leave, which was disclosed under "Exceptional items". <BR> Thereafter, based on subsequent FAQ's and clarifications issued by the Ministry of Labour, deliberations at various forums and detailed examination of various provisions of the above new Labour Codes, the Company, based on Actuarial Valuation, has determined that the incremental estimated liabilities as on March 31, 2026 on account of past service cost in relation to Gratuity and Leave liability amounted to only Rs.657.35 Lakhs. Hence the excess provision of Rs.53.92 Lakhs in December 2025 quarter has been reversed in the March 2026 quarter under "Exceptional items". The net impact of such re assessment has been appropriately accounted for in the statement of profit and loss. <BR> The Company continues to monitor the finalisation of Central 1 State Rules and further clarifications from the Government on other aspects of the Labour Codes and will account for any additional impact, if required, based on such developments. <BR> 4. 99,02,705 fully paid up Equity Shares of face value ~ 101- each of the Company was allotted on 27th June 2023 by way of Qualified Institutional Placement (QIP) whereby proceeds of Rs.39180 Lakhs (Net of Share issue expenses) was raised. <BR> As on March 31 , 2026 the entire net Proceeds of Rs.39180 Lakhs was received by the Company under the QIP and the Statement of Net funds raised and its utilisation is furnished below : <BR> <BR> Statement of QIP Net Funds raised and utilisation <BR> Particulars Amount as stated in Total amount utilised Balance amount as on Remarks <BR> the Offer Document upto March 31, 2026 on March 31, 2026 kept <BR> Rs. In Lakhs Rs. In Lakhs in Fixed Deposits in lakhs <BR> <BR> 1)Investment in OBPL, subsidiary, <BR> for setting up Jammu <BR> Manufacturing Facility 13500 7302 6198 <BR> 2)Repayment/prepayment, in <BR> full or in part, of certain <BR> outstanding borrowings <BR> availed by the company 19546 19546 - <BR> 3)Funding capital expenditure <BR> requirements for setting up a <BR> new block at the API facility <BR> of the Company in Alathur, <BR> Tamil Nadu 36 36 - <BR> 4)General corporate purposes 6372 6372 0 # <BR> Total 39454 33256 6198 <BR> # As per QIP Offer Document the amount allocated for General Corporate Purpose (GCP) was Rs. 6098 Lakhs which was based on the propsoed net proceeds after issue expenses being Rs.39180 Lakhs. However, net proceeds transferred to Monitoring Agency Account was Rs. 39454 Lakhs as against the proposed Net Proceeds of Rs. 39180 Lakhs, therefore surplus Amount of Rs. 274 Lakhs has been included in GCP Balance as on March 31, 2026. The allocation among the objects has been revised vide Shareholder's Resolution dated September 20, 2025. <BR> <BR> 5. The operations of the Company falls under a single operating segment i.e., "Pharmaceuticals" in accordance with Ind AS 108 "Operating Segments" and hence no reporting as per Ind AS 108 is applicable. <BR> <BR> 6. The figures for the quarters ended 31st March, 2026 and 31st March, 2025 are the balancing figures between audited figures in respect of the full financial year and year to date figures up to the third quarter of the relevant financial years which were subjected to limited review. <BR> <BR> 7 The Company has submitted a petition with the Hon'ble National Company law Tribunal, Chennai bench, for amalgamation of its Holding Company Dhanuka laboratories Limited ("the Amalgamating Company") with the Company in compliance with Section 230-232 and other relevant provisions of the Companies Act 2013 . The scheme of amalgamation had been approved by the Board of Directors of the respective Companies. Further, in compliance with the SEBI Listing Regulations and Master Circulars issued thereon, the Company has obtained Observation letter from the BSE Limited and National Stock Exchange of India Limited ("stock exchanges") giving No objection to the said amalgamation. <BR> <BR> The requisite approvals of the concerned shareholders and creditors, as directed by the Hon'ble NCl T have been duly secured. Further, the Companies submitted the Joint Company Petition seeking approval on the Scheme of <BR> Amalgamation. During its hearing held on March 18, 2026, Hon'ble NClT reserved the matter for pronouncement of order, which is presently awaited. <BR> <BR> 8 The Company has successfully completed the acquisition of 100% assets of Allecra Therapeutics GmbH, Germany and Allecra Therapeutics SAS, France on October 29,2025 and August 01,2025 respectively. After the successful completion of above transactions, Orchid Pharma Limited now possesses 100% global ownership of Enmetazobactam (International Brand Name known as EXBLIFEP) (known as Orblicef in India), consolidating rights and control previously split across entities. This will mark the full repatriation of the first novel antibiotic molecule discovered in India, back to India. <BR> <BR> 9 The Company have acquired 100% Share Capital of Weilchensee 1272. V V GmbH, a Company incorporated under laws of Germany, now a Wholly owned subsidiary renamed as Orchid Pharma Europe GmbH w.e.f. July 30, <BR> 2025. <BR> <BR> 10 Figures of the previous period have been regroupted/reclassified restated wherever considered necessary2025-04-012026-03-31AuditedConsolidated8113273000351733000846500600046233690001687200061851200091469200013258700035452700015285450008189104000275902000-657350002101670000-1916000-19160000212083000000-661300020547000089690002144390005071910001004.054.05004.054.05Other Expenses385076000Other Expenses1528545000613223400034052110000059590007307980000052711100000141952100019466320004928900012270123000256411400002638711000700800007620310000862900034794510002580100076669200068360580000292800019109109000507191000123706590001287785000012877850000327727000000047248000332451800011704000000344155800029751000043510000225551500022990250003854000260038900018799400013180002789701000623125900019109109000Other financial assets35562000Non current tax assets (net)487117000Other non current assets896842000Right of use assets49289000Other financial assets8629000Other current assets766692000Lease liability47248000Lease liability3854000Other current liabilities187994000132587000699601000-1409420000-2282930000713600000610390000003545270000012290300000-771370000-840280000000-168056000-724330000774960000985127000000-26826000010119530000003647900000009048400038358100000000000000000000001058350000823226000-28527440000000000018472710001285230000018945000001699803000-1409880000-14098800021106800070080000Item that will not be recalissified to profit or loss88200008820000Item that will not be recalissified to profit or loss89690008969000000088200008969000AuditedQualified opinionSinghi and Co.true2028-08-3184583930008458393000825292300082529230002054700002054700004.054.051910911900019109119000623125900062312590001287786000012877860000The Consolidated Financial Statements for the year ended March 31, 2026 include the financial statements for the year ended March 31, 2026, of the following subsidiary companies: <br></br> (i) Orchid Pharmaceuticals Inc., USA <br></br> (ii) Bexel Pharmaceuticals Inc., USA <br></br> (iii) Diakron Pharmaceuticals, Inc. USA <br></br> <br></br> We did not audit the financial statements of the above subsidiaries whose financial statements reflect total Assets of Rs.385.59 Lakhs as at March 31, 2026, total revenue from operations of Rs. Nil, total comprehensive income after tax of Rs.Nil for the quarter and year ended March 31, 2026 and net cash flows amounting to Rs. Nil for the year ended on that date as considered in the consolidated financial statements. <br></br> The financial statements of the above subsidiaries are unaudited and have been furnished to us by the management and our opinion on the Consolidated financial statements, in so far as it relates to the amounts and disclosures included in respect of the subsidiaries, is based solely on such unaudited financial statements. Accordingly, we do not express any opinion on the completeness and true and fair view of the financial statements, including adjustments, if any, required on the carrying amount of assets and liabilities of the above subsidiaries and foreign currency translation reserve as at March 31, 2026 included in the consolidated financial statements. This has also been qualified in the Limited Review reports of the earlier quarters and audit reports of the earlier years. <br></br> Qualified opinionRepetitiveNot Applicable <br></br> Not ApplicableThe subsidiaries of the Company are located in USA. Audit is not compulsory for companies in USA, if they are not publicly traded. Further transactions in majority of the above subsidiaries are either Nil or insignificant. Hence the management has used unaudited financials for the purpose of consolidationRefer, Basis for Qualified Opinion, in our audit report. <br></br> Manish DhanukaSunil Kumar GuptaManoj GoyalSinghi and Co.Gurugram2026-05-25